Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-RM-22-016

Platform Clinical Trials of Genome Editors in Multiple Diseases (UG3/UH3, Clinical Trial Required)

Closed on November 10, 2022.

Posted
April 11, 2022
Close date
November 10, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $5,019,038 in first-year total cost, median $5,019,038.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 MGG-M (70)]1

Most frequent institutions

  1. YALE UNIVERSITY1
Competing awards under RFA-RM-22-016 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023A non-viral CRISPR-mediated genome editing delivery platform as a potential therapy for neurogenetic diseases1UG3TR004713-01BERRY-KRAVIS, ELIZABETH MARAJIANG, YONG-HUIZHOU, JIANGBINGYALE UNIVERSITY, CT$5,019,038ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
RFA-RM-22-016: Platform Clinical Trials of Genome Editors in Multiple Diseases (UG3/UH3, Clinical Trial Required) | ScienceDex | ConductScience